Trial Profile
A study to investigate the effects of circadian-timed daily administration of bromocriptine-QR [Cycloset] versus placebo in patients with type 2 diabetes whose blood glucose levels were poorly controlled on high dose insulin therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2015
Price :
$35
*
At a glance
- Drugs Bromocriptine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 12 Jun 2015 New trial record
- 06 Jun 2015 Results presented at the American Diabetes Association's 75th Scientific Sessions, according to a VeroScience media release.